XML 34 R24.htm IDEA: XBRL DOCUMENT
v3.25.2

Segment Information (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2025
Segment Information |
Schedule of research and development costs | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Three Months Ended | ​ | Six Months Ended | ​ | Six Months Ended
​ |  | June 30, 2025 |  | June 30, 2024 |  | June 30, 2025 |  | June 30, 2024
​ | ​ | (In thousands)
Barzolvolimab/Anti-KIT Program | ​ | $ | 42,645 | ​ | $ | 30,472 | ​ | $ | 82,348 | ​ | $ | 54,250
CDX-622 | ​ |  | 3,838 | ​ |  | 3,126 | ​ |  | 9,289 | ​ |  | 6,547
Other Programs (a) | ​ |  | 7,713 | ​ |  | 6,089 | ​ |  | 15,173 | ​ |  | 10,551
Total R&D Expense | ​ | $ | 54,196 | ​ | $ | 39,687 | ​ | $ | 106,810 | ​ | $ | 71,348
​
| (a) | Other program expenses primarily include research and development expenses related to early-stage programs, revenue-generating programs and discontinued programs.
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Three Months Ended | ​ | Six Months Ended | ​ | Six Months Ended
​ |  | June 30, 2025 |  | June 30, 2024 |  | June 30, 2025 |  | June 30, 2024
​ |  | (In thousands)
Personnel | ​ | $ | 14,129 | ​ | $ | 11,881 | ​ | $ | 27,729 | ​ | $ | 23,321
Laboratory supplies | ​ |  | 1,544 | ​ |  | 1,615 | ​ |  | 3,712 | ​ |  | 2,923
Facility | ​ |  | 1,398 | ​ |  | 1,250 | ​ |  | 2,803 | ​ |  | 2,536
Product development (b) | ​ |  | 33,536 | ​ |  | 22,667 | ​ |  | 65,702 | ​ |  | 38,192
Other expenses (c) | ​ |  | 3,589 | ​ |  | 2,274 | ​ |  | 6,864 | ​ |  | 4,376
Total R&D expense | ​ | $ | 54,196 | ​ | $ | 39,687 | ​ | $ | 106,810 | ​ | $ | 71,348
​
| (b) | Product development expenses include clinical investigator site fees, external trial monitoring costs, data accumulation costs, contracted research and outside clinical drug product manufacturing.
| (c) | Other expenses primarily include research and development consulting, insurance, licensing and software expenses.

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration